Double-blind cross-over study of the effect of sultosilic-acid pioerazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia

• Published in: Atherosclerosis Vol. 49; no. 2; pp. 109 - 118
• Main Authors: Vinazzer, H., Farine, J.C.
• Format: Journal Article
• Language: English
• Published: Elsevier Ireland Ltd 1983
• Subjects: Bezafibrate; Fibrinolysis; Hyperlipoproteinemia; Platelet adhesion; Sultosilic acid piperazine salt; Platelet adhesion; Hyperlipoproteinemia; Bezafibrate; Sultosilic acid piperazine salt; Fibrinolysis
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/0021-9150(83)90188-0

Sultosilic acid piperazine salt (A-585), a new lipid lowering drug, was compared with the action of bezafibrate. In 20 patients suffering from primary hyperlipoproteinemia a double-blind cross-over study was carried out. A series of parameters of the lipoprotein metabolism, as well as of fibrinolysis and platelet function, was compared before and after administration of the drugs. There was a statistically significant diminution of toral cholesterol, triglycerides, β- and pre-β-cholesterol and an increase of α-cholesterol by both drugs. Furthermore, both drugs caused a significant shortening of the euglobulin lysis time and a significant diminution of platelet adhesiveness. In patients who were under oral anticoagulants the thrombotest levels were not influenced by A-585 but were frequently below the therapeutic range during bezafibrate therapy. The difference in the thrombotest during treatment with the 2 drugs was significant. A slightly elevated γ-GT activity normalized during bezafibrate therapy but was not influenced by A-585. Other parameters did not show significant differences between the 2 drugs.